Literature DB >> 32036585

Cerebrospinal fluid biomarkers implicated in the pathogenesis of anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis.

Junji Ikeda1, Yasuhiro Shimojima2, Yoko Usami3, Ken-Ichi Ueno1, Dai Kishida1, Yoshiki Sekijima1,4.   

Abstract

OBJECTIVE: Hypertrophic pachymeningitis (HP) related to anti-neutrophil cytoplasmic antibody (ANCA) is the most frequently seen immune-mediated HP. We investigated cerebrospinal fluid (CSF) biomarkers related to the pathogenesis of ANCA-related HP (ANCA-HP).
METHODS: The levels of B cell activation factor of the tumor necrosis factor family (BAFF), a proliferation-inducing ligand (APRIL), and transforming growth factor beta 1 (TGF-β1) in the CSF were compared between patients with ANCA-HP (n = 12), other types of immune-mediated HP (other HP; n = 12), multiple sclerosis (MS; n = 14), and non-inflammatory neurological disorders (NIND; n = 10). In addition, we evaluated whether ANCA would be detected in CSF.
RESULTS: CSF levels of BAFF, APRIL, and TGF-β1 were significantly increased in ANCA-HP and other HP. In particular, BAFF and APRIL levels were significantly correlated with the IgG index in ANCA-HP. In other HP, BAFF and APRIL levels were significantly correlated with cell counts and protein levels in CSF. Of 12 patients with ANCA-HP, the CSF of 7 patients (58%) tested positive for myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA, while none of the CSF samples from other HP, MS, or NIND patients tested positive.
CONCLUSION: The levels of BAFF, APRIL, and TGF-β1 may serve as useful CSF biomarkers for assessing the disease activity of immune-mediated HP. Moreover, BAFF and APRIL in the CSF may be implicated in the pathogenesis of ANCA-HP via promoting autoreactive B cells, while detecting MPO- or PR3-ANCA in the CSF may be found in some patients with ANCA-HP.Key Points• CSF BAFF, APRIL, and TGF-β1 levels increase significantly in immune-mediated HP.• CSF BAFF and APRIL levels are significantly correlated with IgG index in ANCA-HP.• Detection of MPO- or PR3-ANCA in the CSF is found in some patients with ANCA-HP.• BAFF, APRIL, and ANCA in the CSF may be implicated in the pathogenesis of ANCA-HP.

Entities:  

Keywords:  A proliferation-inducing ligand; Anti-neutrophil cytoplasmic antibody; B cell activation factor of TNF family; Cerebrospinal fluid; Hypertrophic pachymeningitis; Transforming growth factor beta 1

Mesh:

Substances:

Year:  2020        PMID: 32036585     DOI: 10.1007/s10067-020-04971-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse.

Authors:  Honghao Wang; Kai Wang; Xiaonan Zhong; Wei Qiu; Yongqiang Dai; Aimin Wu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-05-30       Impact factor: 8.317

2.  A nationwide survey of hypertrophic pachymeningitis in Japan.

Authors:  Tomomi Yonekawa; Hiroyuki Murai; Satoshi Utsuki; Takuya Matsushita; Katsuhisa Masaki; Noriko Isobe; Ryo Yamasaki; Mari Yoshida; Susumu Kusunoki; Kiyomi Sakata; Kiyotaka Fujii; Jun-ichi Kira
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-22       Impact factor: 10.154

3.  Increased BAFF and APRIL levels in the cerebrospinal fluid of patients with anti-neutrophil cytoplasmic antibody-related hypertrophic pachymeningitis.

Authors:  Yasuhiro Shimojima; Dai Kishida; Yoshiki Sekijima
Journal:  Cytokine       Date:  2017-08-25       Impact factor: 3.861

4.  Hypertrophic pachymeningitis is a characteristic manifestation of granulomatosis with polyangiitis: A retrospective study of anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Yasuhiro Shimojima; Dai Kishida; Akiyo Hineno; Masahide Yazaki; Yoshiki Sekijima; Shu-Ichi Ikeda
Journal:  Int J Rheum Dis       Date:  2017-02-20       Impact factor: 2.454

5.  Cerebrospinal fluid cytokine/chemokine/growth factor profiles in idiopathic hypertrophic pachymeningitis.

Authors:  Xu Zhang; Takayuki Fujii; Hidenori Ogata; Ryo Yamasaki; Katsuhisa Masaki; Yiwen Cui; Takuya Matsushita; Noriko Isobe; Jun-Ichi Kira
Journal:  J Neuroimmunol       Date:  2019-02-13       Impact factor: 3.478

6.  BAFF is up-regulated in central nervous system of neuro-Behçet's disease.

Authors:  Kamel Hamzaoui; Habib Houman; Faycal Hentati; Agnes Hamzaoui
Journal:  J Neuroimmunol       Date:  2008-07-14       Impact factor: 3.478

7.  Idiopathic hypertrophic pachymeningitis.

Authors:  Shigeo Riku; Shigenori Kato
Journal:  Neuropathology       Date:  2003-12       Impact factor: 1.906

8.  Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody.

Authors:  Akiko Yokoseki; Etsuji Saji; Musashi Arakawa; Takayuki Kosaka; Mariko Hokari; Yasuko Toyoshima; Kouichirou Okamoto; Shigeki Takeda; Kazuhiro Sanpei; Hirotoshi Kikuchi; Shunsei Hirohata; Kouhei Akazawa; Akiyoshi Kakita; Hitoshi Takahashi; Masatoyo Nishizawa; Izumi Kawachi
Journal:  Brain       Date:  2013-11-22       Impact factor: 13.501

9.  Elevated BAFF levels in the cerebrospinal fluid of patients with neuro-Behçet's disease: BAFF is correlated with progressive dementia and psychosis.

Authors:  Y Sumita; Y Murakawa; T Sugiura; Y Wada; A Nagai; S Yamaguchi
Journal:  Scand J Immunol       Date:  2012-06       Impact factor: 3.487

10.  Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.

Authors:  Annie George-Chandy; Estelle Trysberg; Kristina Eriksson
Journal:  Arthritis Res Ther       Date:  2008-08-22       Impact factor: 5.156

View more
  4 in total

Review 1.  Hypertrophic pachymeningitis in polyarteritis nodosa: a case-based review.

Authors:  Shun Nomura; Yasuhiro Shimojima; Yasufumi Kondo; Dai Kishida; Yoshiki Sekijima
Journal:  Clin Rheumatol       Date:  2021-11-02       Impact factor: 2.980

2.  Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).

Authors:  Yasuhiro Shimojima; Dai Kishida; Takanori Ichikawa; Takashi Kida; Nobuyuki Yajima; Satoshi Omura; Daiki Nakagomi; Yoshiyuki Abe; Masatoshi Kadoya; Naoho Takizawa; Atsushi Nomura; Yuji Kukida; Naoya Kondo; Yasuhiko Yamano; Takuya Yanagida; Koji Endo; Shintaro Hirata; Kiyoshi Matsui; Tohru Takeuchi; Kunihiro Ichinose; Masaru Kato; Ryo Yanai; Yusuke Matsuo; Ryo Nishioka; Ryota Okazaki; Tomoaki Takata; Takafumi Ito; Mayuko Moriyama; Ayuko Takatani; Yoshia Miyawaki; Toshiko Ito-Ihara; Takashi Kawaguchi; Yutaka Kawahito; Yoshiki Sekijima
Journal:  Arthritis Res Ther       Date:  2022-08-23       Impact factor: 5.606

3.  IgG4-related hypertrophic pachymeningitis with ANCA-positivity: A case series report and literature review.

Authors:  Cheng Xia; Ping Li
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

4.  Hypertrophic Pachymeningitis in Chinese Patients: Presentation, Radiological Findings, and Clinical Course.

Authors:  Zhuajin Bi; Ke Shang; Jie Cao; Zhuyi Su; Bitao Bu; Shabei Xu; Chenchen Liu
Journal:  Biomed Res Int       Date:  2020-08-14       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.